Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Critical reflection about socioeconomic inequalities among White young men from poor and working-class backgrounds.

Hershberg RM, Johnson SK.

Dev Psychol. 2019 Mar;55(3):562-573. doi: 10.1037/dev0000587.

PMID:
30802107
2.

Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.

Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, Jimeno A, Adkins DR, Schneider CJ, Sacco AG, Shirai K, Bowles DW, Gibson M, Nwizu T, Gottardo R, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Cohen EEW.

JAMA Oncol. 2018 Nov 1;4(11):1583-1588. doi: 10.1001/jamaoncol.2018.1888.

3.

Mycobacterium tuberculosis Transfer RNA Induces IL-12p70 via Synergistic Activation of Pattern Recognition Receptors within a Cell Network.

Keegan C, Krutzik S, Schenk M, Scumpia PO, Lu J, Pang YLJ, Russell BS, Lim KS, Shell S, Prestwich E, Su D, Elashoff D, Hershberg RM, Bloom BR, Belisle JT, Fortune S, Dedon PC, Pellegrini M, Modlin RL.

J Immunol. 2018 May 1;200(9):3244-3258. doi: 10.4049/jimmunol.1701733. Epub 2018 Apr 2.

4.

Development and Pilot Testing of a Bilingual Environmental Health Assessment Tool to Promote Asthma-friendly Childcares.

Evans-Agnew RA, Postma J, Camacho AO, Hershberg RM, Trujilio E, Tinajera M.

Prog Community Health Partnersh. 2018;12(1):35-44. doi: 10.1353/cpr.2018.0004.

PMID:
29606691
5.

Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.

Shayan G, Kansy BA, Gibson SP, Srivastava RM, Bryan JK, Bauman JE, Ohr J, Kim S, Duvvuri U, Clump DA, Heron DE, Johnson JT, Hershberg RM, Ferris RL.

Clin Cancer Res. 2018 Jan 1;24(1):62-72. doi: 10.1158/1078-0432.CCR-17-0357. Epub 2017 Oct 23.

6.

Is the Scoutreach Initiative of Boy Scouts of America Linked to Character Development among Socioeconomically, Racially, and Ethnically Diverse Youth?: Initial Explorations.

Wang J, Champine RB, Ferris KA, Hershberg RM, Warren DJ, Burkhard BM, Su S, Lerner RM.

J Youth Adolesc. 2017 Oct;46(10):2230-2240. doi: 10.1007/s10964-017-0710-8. Epub 2017 Jun 29.

PMID:
28664312
7.

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.

Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G.

Ann Oncol. 2017 May 1;28(5):996-1004. doi: 10.1093/annonc/mdx049.

8.

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.

Chow LQM, Morishima C, Eaton KD, Baik CS, Goulart BH, Anderson LN, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Disis ML, Martins RG.

Clin Cancer Res. 2017 May 15;23(10):2442-2450. doi: 10.1158/1078-0432.CCR-16-1934. Epub 2016 Nov 3.

9.

Age-Specific Adjuvant Synergy: Dual TLR7/8 and Mincle Activation of Human Newborn Dendritic Cells Enables Th1 Polarization.

van Haren SD, Dowling DJ, Foppen W, Christensen D, Andersen P, Reed SG, Hershberg RM, Baden LR, Levy O.

J Immunol. 2016 Dec 1;197(11):4413-4424. Epub 2016 Oct 28.

10.

Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy.

Monk BJ, Facciabene A, Brady WE, Aghajanian CA, Fracasso PM, Walker JL, Lankes HA, Manjarrez KL, Danet-Desnoyers GH, Bell-McGuinn KM, McCourt CK, Malykhin A, Hershberg RM, Coukos G.

Clin Cancer Res. 2017 Apr 15;23(8):1955-1966. doi: 10.1158/1078-0432.CCR-16-1453. Epub 2016 Oct 4.

11.

Character Development within Youth Development Programs: Exploring Multiple Dimensions of Activity Involvement.

Lynch AD, Ferris KA, Burkhard B, Wang J, Hershberg RM, Lerner RM.

Am J Community Psychol. 2016 Mar;57(1-2):73-86. doi: 10.1002/ajcp.12035. Epub 2016 Mar 28.

PMID:
27217313
12.

VTX-1463, a novel TLR-8 agonist, attenuates nasal congestion after ragweed challenge in sensitized beagle dogs.

Royer CM, Rudolph K, Dietsch GN, Hershberg RM, Barrett EG.

Immun Inflamm Dis. 2015 Dec 7;4(1):45-51. doi: 10.1002/iid3.91. eCollection 2016 Mar.

13.

Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity.

Dietsch GN, Lu H, Yang Y, Morishima C, Chow LQ, Disis ML, Hershberg RM.

PLoS One. 2016 Feb 29;11(2):e0148764. doi: 10.1371/journal.pone.0148764. eCollection 2016.

14.

Toll-like Receptor 4 Ligands Down-regulate Fcγ Receptor IIb (FcγRIIb) via MARCH3 Protein-mediated Ubiquitination.

Fatehchand K, Ren L, Elavazhagan S, Fang H, Mo X, Vasilakos JP, Dietsch GN, Hershberg RM, Tridandapani S, Butchar JP.

J Biol Chem. 2016 Feb 19;291(8):3895-904. doi: 10.1074/jbc.M115.701151. Epub 2015 Dec 22.

15.

Developmental Trajectories of Youth Character: A Five-Wave Longitudinal Study of Cub Scouts and Non-Scout Boys.

Wang J, Ferris KA, Hershberg RM, Lerner RM.

J Youth Adolesc. 2015 Dec;44(12):2359-73. doi: 10.1007/s10964-015-0340-y. Epub 2015 Aug 18.

PMID:
26280400
16.

Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337).

Dietsch GN, Randall TD, Gottardo R, Northfelt DW, Ramanathan RK, Cohen PA, Manjarrez KL, Newkirk M, Bryan JK, Hershberg RM.

Clin Cancer Res. 2015 Dec 15;21(24):5445-52. doi: 10.1158/1078-0432.CCR-15-0578. Epub 2015 Jul 7.

17.

Granzyme B expression is enhanced in human monocytes by TLR8 agonists and contributes to antibody-dependent cellular cytotoxicity.

Elavazhagan S, Fatehchand K, Santhanam V, Fang H, Ren L, Gautam S, Reader B, Mo X, Cheney C, Briercheck E, Vasilakos JP, Dietsch GN, Hershberg RM, Caligiuri M, Byrd JC, Butchar JP, Tridandapani S.

J Immunol. 2015 Mar 15;194(6):2786-95. doi: 10.4049/jimmunol.1402316. Epub 2015 Feb 9.

18.

A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma.

Northfelt DW, Ramanathan RK, Cohen PA, Von Hoff DD, Weiss GJ, Dietsch GN, Manjarrez KL, Randall TD, Hershberg RM.

Clin Cancer Res. 2014 Jul 15;20(14):3683-91. doi: 10.1158/1078-0432.CCR-14-0392. Epub 2014 May 7.

19.

Illuminating trajectories of adolescent thriving and contribution through the words of youth: qualitative findings from the 4-H Study of Positive Youth Development.

Hershberg RM, DeSouza LM, Warren AE, Lerner JV, Lerner RM.

J Youth Adolesc. 2014 Jun;43(6):950-70. doi: 10.1007/s10964-014-0102-2. Epub 2014 Feb 21.

PMID:
24557778
20.

Beyond the deficit model: bullying and trajectories of character virtues in adolescence.

Hilliard LJ, Bowers EP, Greenman KN, Hershberg RM, Geldhof GJ, Glickman SA, Lerner JV, Lerner RM.

J Youth Adolesc. 2014 Jun;43(6):991-1003. doi: 10.1007/s10964-014-0094-y. Epub 2014 Feb 16.

PMID:
24531881
21.

The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes.

Dowling DJ, Tan Z, Prokopowicz ZM, Palmer CD, Matthews MA, Dietsch GN, Hershberg RM, Levy O.

PLoS One. 2013;8(3):e58164. doi: 10.1371/journal.pone.0058164. Epub 2013 Mar 4.

22.

Lineage targeted MHC-II transgenic mice demonstrate the role of dendritic cells in bacterial-driven colitis.

Maggio-Price L, Seamons A, Bielefeldt-Ohmann H, Zeng W, Brabb T, Ware C, Lei M, Hershberg RM.

Inflamm Bowel Dis. 2013 Jan;19(1):174-84. doi: 10.1002/ibd.23000.

23.

VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.

Lu H, Dietsch GN, Matthews MA, Yang Y, Ghanekar S, Inokuma M, Suni M, Maino VC, Henderson KE, Howbert JJ, Disis ML, Hershberg RM.

Clin Cancer Res. 2012 Jan 15;18(2):499-509. doi: 10.1158/1078-0432.CCR-11-1625. Epub 2011 Nov 29.

24.

Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations.

Papadakis KA, Yang H, Ippoliti A, Mei L, Elson CO, Hershberg RM, Vasiliauskas EA, Fleshner PR, Abreu MT, Taylor K, Landers CJ, Rotter JI, Targan SR.

Inflamm Bowel Dis. 2007 May;13(5):524-30.

PMID:
17260364
25.

Molecular approaches to the role of the microbiota in inflammatory bowel disease.

Elson CO, Cong Y, Qi F, Hershberg RM, Targan SR.

Ann N Y Acad Sci. 2006 Aug;1072:39-51.

PMID:
17057189
26.

Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells.

Lin AM, Hershberg RM, Small EJ.

Urol Oncol. 2006 Sep-Oct;24(5):434-41. Review.

PMID:
16962496
27.

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM.

J Clin Oncol. 2006 Jul 1;24(19):3089-94.

PMID:
16809734
29.

Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression.

Dubinsky MC, Lin YC, Dutridge D, Picornell Y, Landers CJ, Farrior S, Wrobel I, Quiros A, Vasiliauskas EA, Grill B, Israel D, Bahar R, Christie D, Wahbeh G, Silber G, Dallazadeh S, Shah P, Thomas D, Kelts D, Hershberg RM, Elson CO, Targan SR, Taylor KD, Rotter JI, Yang H; Western Regional Pediatric IBD Research Alliance.

Am J Gastroenterol. 2006 Feb;101(2):360-7.

30.

Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease.

Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, Vasiliauskas E, Elson CO, Hershberg RM.

Gastroenterology. 2005 Jun;128(7):2020-8.

PMID:
15940634
31.

A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease.

Fort MM, Mozaffarian A, Stöver AG, Correia Jda S, Johnson DA, Crane RT, Ulevitch RJ, Persing DH, Bielefeldt-Ohmann H, Probst P, Jeffery E, Fling SP, Hershberg RM.

J Immunol. 2005 May 15;174(10):6416-23.

32.

Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge.

Cluff CW, Baldridge JR, Stöver AG, Evans JT, Johnson DA, Lacy MJ, Clawson VG, Yorgensen VM, Johnson CL, Livesay MT, Hershberg RM, Persing DH.

Infect Immun. 2005 May;73(5):3044-52.

33.

Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer.

Schellhammer PF, Hershberg RM.

World J Urol. 2005 Feb;23(1):47-9. Epub 2005 Jan 13.

PMID:
15647927
34.

Bacterial flagellin is a dominant antigen in Crohn disease.

Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR, Fort M, Hershberg RM.

J Clin Invest. 2004 May;113(9):1296-306.

35.

Colonic bacterial superantigens evoke an inflammatory response and exaggerate disease in mice recovering from colitis.

Lu J, Wang A, Ansari S, Hershberg RM, McKay DM.

Gastroenterology. 2003 Dec;125(6):1785-95.

PMID:
14724831
36.

Structure-activity relationship of synthetic toll-like receptor 4 agonists.

Stöver AG, Da Silva Correia J, Evans JT, Cluff CW, Elliott MW, Jeffery EW, Johnson DA, Lacy MJ, Baldridge JR, Probst P, Ulevitch RJ, Persing DH, Hershberg RM.

J Biol Chem. 2004 Feb 6;279(6):4440-9. Epub 2003 Oct 21.

37.

Taking toll: lipid A mimetics as adjuvants and immunomodulators.

Persing DH, Coler RN, Lacy MJ, Johnson DA, Baldridge JR, Hershberg RM, Reed SG.

Trends Microbiol. 2002;10(10 Suppl):S32-7. Review.

PMID:
12377566
39.

Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia.

Furuta GT, Turner JR, Taylor CT, Hershberg RM, Comerford K, Narravula S, Podolsky DK, Colgan SP.

J Exp Med. 2001 May 7;193(9):1027-34.

40.

Human CD1d associates with prolyl-4-hydroxylase during its biosynthesis.

Kim HS, Colgan SP, Pitman R, Hershberg RM, Blumberg RS.

Mol Immunol. 2000 Oct;37(14):861-8.

PMID:
11257307
41.

Antigen processing and presentation by intestinal epithelial cells - polarity and complexity.

Hershberg RM, Mayer LF.

Immunol Today. 2000 Mar;21(3):123-8. Review.

PMID:
10689299
42.

Ligation of intestinal epithelial CD1d induces bioactive IL-10: critical role of the cytoplasmic tail in autocrine signaling.

Colgan SP, Hershberg RM, Furuta GT, Blumberg RS.

Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13938-43.

43.

What's so (Co)stimulating about the intestinal epithelium?

Hershberg RM, Blumberg RS.

Gastroenterology. 1999 Sep;117(3):726-8. No abstract available.

PMID:
10464150
44.
45.

Polarized expression and function of the costimulatory molecule CD58 on human intestinal epithelial cells.

Framson PE, Cho DH, Lee LY, Hershberg RM.

Gastroenterology. 1999 May;116(5):1054-62.

PMID:
10220497
46.

Highly polarized HLA class II antigen processing and presentation by human intestinal epithelial cells.

Hershberg RM, Cho DH, Youakim A, Bradley MB, Lee JS, Framson PE, Nepom GT.

J Clin Invest. 1998 Aug 15;102(4):792-803.

47.

Intestinal epithelial cells use two distinct pathways for HLA class II antigen processing.

Hershberg RM, Framson PE, Cho DH, Lee LY, Kovats S, Beitz J, Blum JS, Nepom GT.

J Clin Invest. 1997 Jul 1;100(1):204-15.

48.

Depletion of mouse alpha beta T cell antigen receptor bearing lymphocytes by neonatal monoclonal antibody treatment.

Mixter PF, Sydora BC, Hershberg RM, Kronenberg M.

J Immunol. 1991 Dec 15;147(12):4109-17.

PMID:
1836478
49.

Insertion of hypoxanthine phosphoribosyltransferase cDNA into human bone marrow cells by a retrovirus.

Gruber HE, Finley KD, Luchtman LA, Hershberg RM, Katzman SS, Laikind PK, Meyers EN, Seegmiller JE, Friedmann T, Yee JK, et al.

Adv Exp Med Biol. 1986;195 Pt A:171-5. No abstract available.

PMID:
3014831
50.

Retroviral vector-mediated gene transfer into human hematopoietic progenitor cells.

Gruber HE, Finley KD, Hershberg RM, Katzman SS, Laikind PK, Seegmiller JE, Friedmann T, Yee JK, Jolly DJ.

Science. 1985 Nov 29;230(4729):1057-61.

PMID:
3864246

Supplemental Content

Loading ...
Support Center